Table 4 The sensitivity analyses of the studies
Sensitivity analyses | No. of studies | No. of patients | PFS HR, (95% CI) | No. of patients | OS HR, (95% CI) |
|---|---|---|---|---|---|
Total studies | 5 | 2 253 | 1.17 (0.83–1.64) | 2 253 | 0.91 (0.83–1.00) |
JAVELIN Gastric 300 excluded | 4 | 1 882 | 1.06 (0.72–1.55) | 1 882 | 0.87 (0.79–0.96) |
KEYNOTE-061 excluded | 4 | 1 858 | 1.14 (0.73–1.78) | 1 858 | 0.93 (0.84–1.02) |
KEYNOTE-062 (Pem vs Chemo) excluded | 4 | 1 997 | 1.06 (0.72–1.57) | 1 997 | 0.91 (0.82–1.01) |
KEYNOTE-062 (Pem + Chemo vs Chemo) excluded | 4 | 1 996 | 1.27 (0.88–1.83) | 1 996 | 0.93 (0.84–1.03) |
ATTRACTION-4 excluded | 4 | 1 529 | 1.32 (0.95–1.85) | 1 529 | 0.91 (0.82–1.01) |